Katz Barrett 4
4 · Viridian Therapeutics, Inc.\DE · Filed Jan 18, 2023
Insider Transaction Report
Form 4
Katz Barrett
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-01-17−24,853→ 267,000 totalExercise: $23.03Exp: 2031-01-17→ Common Stock (24,853 underlying) - Exercise/Conversion
Common Stock
2023-01-13$23.03/sh+4,147$95,505→ 4,147 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-13−4,147→ 291,853 totalExercise: $23.03Exp: 2031-01-17→ Common Stock (4,147 underlying) - Sale
Common Stock
2023-01-13$37.01/sh−4,147$153,480→ 0 total - Sale
Common Stock
2023-01-17$37.21/sh−24,853$924,780→ 0 total - Exercise/Conversion
Common Stock
2023-01-17$23.03/sh+24,853$572,365→ 24,853 total
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.58. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.